{"nctId":"NCT00667992","briefTitle":"Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma","startDateStruct":{"date":"2008-04"},"conditions":["Asthma"],"count":99,"armGroups":[{"label":"Budesonide Hydrofluoroalkane (HFA) 100","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Budesonide HFA"]},{"label":"Budesonide HFA 400","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Budesonide HFA"]},{"label":"Budesonide Chlorofluorocarbon (CFC) 100","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Budesonide CFC"]},{"label":"Budesonide CFC 400","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Budesonide CFC"]}],"interventions":[{"name":"Budesonide HFA","otherNames":[]},{"name":"Budesonide CFC","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients suffering from stable, persistent, mild to moderate asthma as defined by Global Initiative for Asthma (GINA) Guidelines and for whom FEV1 \\> 60 %\n* ICS taking ≤ 1000 μg BDP per day, or equivalent\n* Methacholine PC20 \\< 4 mg/mL\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to budesonide or any other constituents of the budesonide HFA pMDI or budesonide CFC pMDI.\n* Currently a smoker or who has ceased smoking within 6 months of Visit 1.\n* Exacerbations of asthma requiring oral steroids, hospitalisation or change in asthma therapy in the previous three months.\n* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or bronchiectasis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PC 20 Methacholine (Provocative Concentration of Methacholine Causing 20 % Fall in FEV1(Forced Expiratory Volume)","description":"Provocative concentration of methacholine is that causing a 20% fall in FEV1. The methacholine challenge test entailed the patient inhaling from an aerosol containing doubling concentrations of methacholine over a period of 2 minutes until FEV1 had been reduced by 20%.\n\nThe ratio of Methacholine concentration measured at 2 weeks to that at Baseline.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.546","spread":null},{"groupId":"OG001","value":"2.163","spread":null},{"groupId":"OG002","value":"1.673","spread":null},{"groupId":"OG003","value":"2.079","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Exploratory Flow (PEF)","description":"Change in PEF at Week 2 from baseline, mean over all days in run-in and all dasy in treatment period, with baseline as covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"12.7","spread":null},{"groupId":"OG002","value":"12.0","spread":null},{"groupId":"OG003","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 (Forced Expiratory Volume in 1 Second)","description":"FEV1 change from baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.10","spread":null},{"groupId":"OG002","value":"0.10","spread":null},{"groupId":"OG003","value":"0.11","spread":null}]}]}]},{"type":"SECONDARY","title":"FEF 25-75 (Forced Expiratory Flow 25-75)","description":"FEF 25-75- Forced expiratory flow over the middle one half of the FVC. The results are expressed as the change from baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null},{"groupId":"OG001","value":"0.14","spread":null},{"groupId":"OG002","value":"0.15","spread":null},{"groupId":"OG003","value":"0.20","spread":null}]}]}]},{"type":"SECONDARY","title":"eNO (Exhaled Nitrogen Oxide)","description":"eNO ratio of baseline","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":null},{"groupId":"OG001","value":"0.57","spread":null},{"groupId":"OG002","value":"0.66","spread":null},{"groupId":"OG003","value":"0.59","spread":null}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score Morning","description":"Asthma Symptom score recorded daily in the morning: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the morning is presented.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":null},{"groupId":"OG001","value":"0.29","spread":null},{"groupId":"OG002","value":"0.39","spread":null},{"groupId":"OG003","value":"0.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score Evening","description":"Asthma Symptom score recorded daily in the evening: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the evening is presented.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":null},{"groupId":"OG001","value":"0.32","spread":null},{"groupId":"OG002","value":"0.46","spread":null},{"groupId":"OG003","value":"0.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score Total","description":"Asthma Symptom score recoded daily, Total. Scale: 0 - 3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily is presented.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":null},{"groupId":"OG001","value":"0.61","spread":null},{"groupId":"OG002","value":"0.85","spread":null},{"groupId":"OG003","value":"0.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Rescue Medication Morning","description":"The average of means for inhalations of rescue medication in the morning is presented.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null},{"groupId":"OG001","value":"0.45","spread":null},{"groupId":"OG002","value":"0.62","spread":null},{"groupId":"OG003","value":"0.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Rescue Medication Evening","description":"The average of means for inhalations of rescue medication in the evening is presented.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":null},{"groupId":"OG001","value":"0.67","spread":null},{"groupId":"OG002","value":"0.84","spread":null},{"groupId":"OG003","value":"0.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Rescue Medication Total","description":"The average of means for inhalations of rescue medication in morning and evening combined over a 24 hour period is presented.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":null},{"groupId":"OG001","value":"1.10","spread":null},{"groupId":"OG002","value":"1.39","spread":null},{"groupId":"OG003","value":"1.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Exploratory Flow (PEF) Morning","description":"Peak Exploratory Flow (PEF) recorded daily in the morning","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"426","spread":null},{"groupId":"OG001","value":"437","spread":null},{"groupId":"OG002","value":"428","spread":null},{"groupId":"OG003","value":"438","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":86},"commonTop":[]}}}